IDEXX Laboratories Inc
IDXX- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000874716
In the last 90 days, IDEXX Laboratories Inc insiders filed 0 open-market purchases and 1 sale; 1,306 institutions reported holding it in 13F filings for Q2 2026, worth $39.1B in total; 3 superinvestors hold it, including Fundsmith and Weitz Investment Management.
13F holders, Q3 2022
Institutional positions in IDEXX Laboratories Inc as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 925
- −27 vs. Q2 2022
- Shares held
- 73.7M
- −124.5K (−0.2%) vs. Q2 2022
- Total value
- $24.0B
- −$1.91B (−7.4%) vs. Q2 2022
- New holders
- 59
- 336 more added
- Sold out
- 86
- 352 more reduced
7 institutions that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IDXX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1,306 | $39.1B |
| Q1 2026 | 1,318 | $41.2B |
| Q4 2025 | 1,385 | $50.3B |
| Q3 2025 | 1,302 | $46.1B |
| Q2 2025 | 1,234 | $40.0B |
| Q1 2025 | 1,143 | $31.1B |
| Q4 2024 | 1,124 | $29.8B |
| Q3 2024 | 1,117 | $36.7B |
| Q2 2024 | 1,110 | $36.4B |
| Q1 2024 | 1,147 | $39.1B |
| Q4 2023 | 1,155 | $40.5B |
| Q3 2023 | 1,061 | $32.4B |
| Q2 2023 | 1,069 | $36.7B |
| Q1 2023 | 1,058 | $36.4B |
| Q4 2022 | 1,001 | $30.0B |
| Q3 2022 | 925 | $24.0B |
| Q2 2022 | 959 | $25.9B |
| Q1 2022 | 1,036 | $39.7B |
| Q4 2021 | 1,110 | $47.1B |
| Q3 2021 | 1,063 | $44.6B |
| Q2 2021 | 1,037 | $46.1B |
| Q1 2021 | 1,015 | $35.6B |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding IDEXX Laboratories Inc; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sageworth Trust Co of South Dakota | 0 | $0 | 0.00% | −11−100.0% | Sold out |
| Rockbridge Investment Management, LCC | 0 | $0 | 0.00% | −10−100.0% | Sold out |
| Steward Financial Group LLC | 0 | $0 | 0.00% | −11−100.0% | Sold out |
| Northwest Investment Counselors, LLC | 0 | $0 | 0.00% | −5−100.0% | Sold out |
| Horan Securities, Inc. | 0 | $0 | 0.00% | −6−100.0% | Sold out |
| Ahrens Investment Partners LLC | 0 | $0 | 0.00% | −5−100.0% | Sold out |
| WFA of San Diego, LLC | 0 | $0 | 0.00% | −6−100.0% | Sold out |
| Itau Unibanco Holding S.A. | 0 | $0 | 0.00% | −2−100.0% | Sold out |
| Tfo-TDC, LLC | 0 | $0 | 0.00% | −3−100.0% | Sold out |
| American Research & Management Co. | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Bellwether Advisors, LLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Brewin Dolphin Ltd | – | – | – | – | Not filed |
| Advisor Partners LLC | – | – | – | – | Not filed |
| Coldstream Capital Management Inc | – | – | – | – | Not filed |
| Frontier Wealth Management LLC | – | – | – | – | Not filed |
| Fieldpoint Private Securities, LLC | – | – | – | – | Not filed |
| Private Capital Group, LLC | – | – | – | – | Not filed |
| Brewin Dolphin Wealth Management Ltd | – | – | – | – | Not filed |